ArticleNature medicine2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Adam D Cohen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleNature medicine2026
Adam D Cohen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.